The Maintrac Tumour Sphere Units Test
Some CTCs may have stem-cell qualities. These CTCs may have the ability to hide from treatment and form a second tumour, called a metastasis. This test determines whether a person’s CTCs can multiply to form microscopic clusters, called Tumour Sphere Units, in the laboratory. CTCs that can form clusters have stem cell qualities, rendering them more resistant to treatment and capable of initiating metastatic spread of cancer.
Assessing the risk of cancer spread is now possible. The Maintrac® Tumour Sphere Units test can be used to:
- Determine the level of aggressiveness of a person’s cancer
- Assess the potential for cancer spread
- Detect the risk of metastasis, a second tumour, early
This test can only be ordered in addition to a CTC Count. Please note a period of 21 days growth in media is required for this test. This test can only be ordered in addition to a CTC Count test.
The best way to monitor cancer activity and long-term effectiveness of treatment is via a single CTC count test every 3-6 months.
Maintrac® is a state-of-the-art German technology that detects, characterises and tests CTCs. It has been critically validated and published in peer reviewed journals for over 12 years. Maintrac® CTC tests are acknowledged and utilised by many universities, Oncologists and cancer clinics worldwide.
Click here for pricing
To order a test, download the request form and take it with you
to the next appointment with your treating healthcare practitioner.